1. Microvascular complications were uncommon but nevertheless observed when individuals with Raynaud’s phenomenon (RP) or scleroderma were treated with Calcitonin-gene related peptide (CGRP) antagonist therapy.
2. Microvascular complications in patients with RP included facial telangiectasia and necrosis of distal phalanges after CGRP antagonists use.
Evidence Rating: 2 (Good)
Study Rundown: Raynaud’s phenomenon...
Originally published by Harvard Health.
What Is It?
Raynaud’s phenomenon is a blood vessel disorder. The condition is also called Raynaud's disease or Raynaud's syndrome.
When healthy people are in a cold environment, the tiny blood vessels in their skin constrict, or narrow. This is an effort by the body to conserve...